Quick Answer
Sagimet Biosciences Inc. reported Operating Income of -$56.89 million for fiscal year 2025.
Sagimet Biosciences Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$56.89M | -4.5% |
| 2024 | -$54.45M | -77.1% |
| 2023 | -$30.74M | +1.0% |
| 2022 | -$31.05M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$14.33M | +15.2% | -20.2% |
| June 30, 2025 | -$11.93M | -12.6% | +40.0% |
| March 31, 2025 | -$19.86M | -126.6% | -17.5% |
| September 30, 2024 | -$16.90M | -126.8% | -59.6% |
| June 30, 2024 | -$10.59M | -50.0% | -20.8% |
| March 31, 2024 | -$8.77M | -29.6% | -17.7% |
| September 30, 2023 | -$7.45M | +3.0% | -5.6% |
| June 30, 2023 | -$7.06M | +2.5% | -4.3% |
- Sagimet Biosciences Inc. showed a decrease of -4.5% in Operating Income compared to the prior fiscal year.
- Over the 2022–2025 period, Sagimet Biosciences Inc.’s operating income has declined by 83.2% (from -$31.05 million to -$56.89 million).
- The most recent figure is from Sagimet Biosciences Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: